It expands in Serbia.
2017 guidance revised sharply upwardly.
It's a bit unpredictable, though.
The recommendation is 'Hold'.
Despite profit plunge.
Earnings report to be published this week.
An SSD agreement to be exact.
No official announcement yet.
Corporate credit rating is affirmed.
Marketing of key drug green-lighted for Western Europe.
To obtain control over Opimus.
Prospectus released.
Thanks to MTel's high prices.
It explains why.